β-Arrestins
Multifunctional adaptor proteins that regulate G protein-coupled receptor (GPCR) signalling through desensitization and internalization and by promoting signalling through a wide variety of pathways. They also regulate non-GPCR targets, such as receptor tyrosine kinases.
Efficacy
The ability of a ligand to generate a quantifiable response after binding to a receptor.
Affinity
A measurement of how well a ligand binds to a receptor, commonly expressed in terms of a dissociation constant (K d ). Affinity depends on cellular context, and therefore affinity for a G protein-coupled receptor is influenced by transducers, such as G proteins and β-arrestins.
including mitogen-activated protein kinases (MAPKs), the serine/threonine kinase AKT, the tyrosine kinase SRC, nuclear factor-κB (NF-κB) and phosphoinositide 3-kinase (PI3K), by acting as adaptors and scaffolds [11] [12] [13] [14] [15] [16] [17] [18] . These pathways are separate from classical G protein signalling but can involve similar signalling cascades that are often temporally distinct. More recently, it has also been appreciated that some receptors that tightly interact with β-arrestins maintain catalytic GEF activity on endosomes, continuing to promote G protein signalling after internalization [19] [20] [21] . Thus, β-arrestins regulate nearly all aspects of receptor activity, including desensitization, downregulation, trafficking and signalling.
Most drugs that activate or block GPCRs are thought to 'equally' target distinct signalling pathways mediated by different G proteins and β-arrestins. These agonists are thought to amplify downstream signalling pathways in a similar fashion to that of the endogenous reference agonist ('balanced agonists'), while most antagonists are believed to inhibit all second-messenger systems activated by those agonists. However, it was appreciated three decades ago that selective agonists or antagonists could specifically target particular receptor-linked effector systems 22 . Indeed, over the past two decades, a number of ligands have been described that selectively activate some pathways while blocking others downstream of a receptor 23, 24 . Compared with the aforementioned balanced agonists, these 'functionally selective' (REF. 25) or 'biased' agonists can selectively activate G proteins while blocking arrestins, or vice versa 26 . This behaviour was initially identified in a number of GPCR systems, including pituitary adenylate cyclase-activating peptide (PACAP) receptor ligands that differentially activated different G proteins as measured by a reversal in potencies [27] [28] [29] . Biased agonism has become an increasingly active area of research since the discovery of β-arrestin-mediated signalling 30 , with a plethora of biased ligands identified for multiple GPCRs 31, 32 . The discovery of biased agonism has had important implications for our understanding of GPCR biology. First, biased agonism is not consistent with two-state models for receptor signalling, and therefore it alters our concept of efficacy 33 . Second, biased signalling suggests that GPCRs should not be modelled as binary switches but instead should be modelled as allosteric microprocessors that generate a multitude of conformations in response to different ligands. There are also important clinical implications for these ligands, as selectively activating or inhibiting specific signalling cascades could yield more targeted drugs with reduced side effects 34 . In this Review, we primarily focus on advances in the field of biased agonism within the past 5 years that have changed our fundamental understanding of receptor biology, from the theoretical and structural bases for receptor signalling to the design of novel agents with unique therapeutic profiles.
Theoretical basis of biased signalling
What factors result in the development of a biased response? Using the ternary complex as a model for receptor activity, agonist activation of a receptor requires three principal components to initiate signalling: a ligand, a receptor and transducers 35 . These three components interact allosterically 36 : a ligand can increase the affinity of a receptor for a transducer, such as a G protein or β-arrestin, while transducer binding to intracellular receptor domains can stabilize a conformation that increases the affinity for a specific ligand 37, 38 . Allostery is a widespread biological phenomenon that describes the ability of interactions occurring at a site of a macromolecule to modulate interactions at a spatially distinct binding site on the same macromolecule in a reciprocal manner 39 . In two-state models, there are only binary conditions for the receptor: the inactive state, which is incapable of signalling, and the active state, which can bind to and activate transducers 37 . The receptor is modelled as a switch, with agonists stabilizing the 'on' state and antagonists stabilizing the 'off ' state. Agonist efficacy can be defined as the ability of a ligand to modify the signalling state of the receptor by stabilizing the active receptor conformation 40 . The phenomenon of biased agonism demonstrates that receptors are not acting as simple switches that merely encode states of activity across a binary spectrum, that is, either agonists or antagonists that equally activate or inhibit all signalling pathways downstream of a receptor. Rather, ligand binding results in the activation or inhibition of multiple GPCR-mediated effectors. These effectors often rely on distinct phases of G protein, GRK and β-arrestin signalling. Instead of encoding binary 'on' or 'off ' signals, a more appropriate model is one where a GPCR acts as an allosteric microprocessor with pluridimensional efficacy, responding to different molecules with different transducer coupling efficiencies 41, 42 . Any site on the receptor surface that binds to a molecule can, in theory, stabilize a distinct receptor conformation and induce a particular pharmacological output. Therefore, the physiological activity of a drug need not be linked to an interaction at the orthosteric binding site.
Biased signalling is not limited to GPCRs. For example, nuclear hormone receptors can display distinct conformational dynamics when bound to different ligands [43] [44] [45] . Selective oestrogen receptor modulators (SERMs) display tissue-selective pharmacology and highlight the clinical relevance of differential signalling. As oestrogen antagonists, SERMs oppose the action of oestrogens in certain tissues while mimicking the action of endogenous oestrogens (agonists) in other tissue types 46 . Ligands for receptor tyrosine kinases (RTKs) have been discovered that dissociate kinase domain phosphorylation and receptor dimerization 47 . Interestingly, β-arrestin 1 regulates extracellular-signal-regulated kinase (ERK) signalling downstream of the RTK insulin-like growth factor 1 receptor (IGF1R) 48 , suggesting that β-arrestin-biased ligands might be discovered in the RTK family as well. Like GPCRs, selectively modulating the signalling networks of these receptor classes holds immense therapeutic promise. It is likely that we will begin to appreciate biased signalling in other cellular components charged with transducing extracellular stimuli into intracellular responses.
Ligand bias
Biased signalling encoded in the ligand that generates a distinct ligand-receptor conformation relative to a reference ligand.
Allosteric modulators
Ligands that bind to an allosteric site of the receptor and affect receptor responses to orthosteric ligands. Some allosteric modulators are capable of generating biased responses.
Multiple levels of bias Any of the three components of a ternary complex -the ligand, receptor and transducers -can contribute to a biased response (FIG. 1) .
Ligand bias
Ligand bias refers to the situation in which a ligand induces a unique receptor conformation that results in differential coupling to the signal transduction cascade and a biased response relative to a reference agonist (normally an endogenous ligand). Other contributors to bias include kinetics and cellular location. Distinct agonists, as well as peptides with disparate post-translational modifications, can alter intracellular transduction. For example, either differential glycosylation patterning of endogenous follicle-stimulating hormone (FSH) 49 Figure 1 | Biased signalling can be encoded through three general mechanisms. a | A balanced agonist binding to a balanced receptor in an unbiased system may display equivalent potencies for two different pathways, such as G protein and β-arrestin, under assay conditions with similar amplification levels. b | Biased agonism is encoded through a ligand. A ligand-receptor-effector complex generates distinct conformations that preferentially signal through certain pathways relative to other pathways (β-arrestin-biased relative to G protein-biased in this example). Unlike the balanced agonist in part a, a β-arrestin-biased agonist may display a left shift in potency relative to the G protein pathway under the same assay conditions. c | Biased receptors, such as G protein-biased receptors that lack C-terminal phosphorylation sites necessary for β-arrestin recruitment, signal preferentially through one pathway relative to another (G protein-biased signalling in this example) despite being stimulated by a balanced agonist. Similar to biased ligands, biased receptors will also display a left shift of one pathway relative to another that may not be observed at an unbiased receptor under the same assay conditions. d | System bias may be due to differential expression of signalling effectors or other cofactors. For example, higher expression of certain G protein-coupled receptor kinase (GRK) and/or β-arrestin isoforms can bias signalling towards the β-arrestin pathway (shown here). Alternatively, a lack of GRKs or β-arrestins can bias signalling towards the G protein pathway (not shown). E max , maximal effect produced by a ligand.
Biased agonists
Ligands that selectively enhance or attenuate some, but not all, of the signalling pathways available to a receptor compared with a reference ligand (usually an endogenous agonist).
Receptor bias
Biased signalling encoded by differences in receptor structure or conformation compared with the 'wild-type' receptor.
System bias
Biased signalling directed by the relative expression of receptor transducers, such as increased expression of G proteins, G protein-coupled receptor kinases and/or β-arrestins.
Biased agonists can alter the properties of this core ternary complex by binding orthosterically, allosterically or both in a bitopic fashion. Ligand bias should generate a biased response independently of the cell system tested, although if the transducers required for a biased response are either expressed at low levels or absent, then no change in signalling will be observed.
Receptor bias
Receptor bias can be generated by modifying the receptor to change its ability to bind to specific ligands or transducers. This can occur through mutation or through differential splicing, both of which can alter coupling to G proteins and β-arrestins. For example, all 19 possible amino acid substitutions at Ala293 of the α1-adrenergic receptor (α 1 -AR) result in constitutive G protein activity 52 , while a single serine-to-alanine mutation in the C-terminus of the apelin receptor (APJ) inactivates GRK phosphorylation and blunts β-arrestin signalling 53 . In the C-terminus of the neuropeptide Y 4 receptor, mutation of glutamic acid, serine or threonine residues disrupts agonist-induced recruitment of β-arrestin 2 and receptor endocytosis 54 . CXC-chemokine receptor 7 (CXCR7) was initially classified as a non-signalling 'decoy' receptor, although it was later shown that CXCR7 triggers ligand-dependent β-arrestin recruitment and signalling while lacking appreciable G protein signalling 55 . CXCR7 has also been shown to heterodimerize with CXCR4 to alter CXCR4 signalling 56, 57 while also having distinct and independent functions mediated by β-arrestin 58 . The chemokine receptor CXCR3 has splice variants, CXCR3A and CXCR3B, that differentially activate β-arrestins despite only differing in their N-terminal residues 59, 60 . Non-native biased receptors have also been developed. GPCR designer receptors exclusively activated by designer drugs (DREADDs) utilize a chemical-genetic approach for selective activation of a designer GPCR by an otherwise pharmacologically inert compound 61 . Biased DREADDs have recently been designed that selectively activate G protein or β-arrestin signalling in specific cell types 62, 63 . In addition, biased optogenetic GPCRs for both G protein and β-arrestin signalling have been generated, and these chimeric light-sensitive receptors allow precise temporal and spatial pathway dissection 64, 65 . System bias 'System bias' , or 'apparent' biased agonism, can be modulated through the differential expression of transducer elements proximal to the receptor, such as the receptor itself, β-arrestins or GRKs, as well as expression of amplification cascades distal to the receptor 40, 66, 67 (FIG. 1) . Similar to the nuclear hormone receptor system, where a ligand may act as an oestrogen receptor agonist in one tissue but as an antagonist in another 68 , GPCRs also have different signalling properties depending on the tissue or system probed. Such system bias can result in different signalling properties depending on the cell type; for example, certain agonists targeting the dopamine 2 receptor (D 2 R) have different effects in the striatum and prefrontal cortex, which could be related to the differential expression of β-arrestins and GRKs across brain regions 69 . System bias may also differ between species 70 and is important to consider in translational studies. Studies of biased ligands with apparently contradictory results may be due to differences in the experimental system. Part of system bias is 'observation bias' , as all measurements are viewed through the lens of a specific assay that is associated with amplification or other properties. To identify biased agonists, it is crucial to remove the effects of system bias and observation bias from the cellular response 40 .
Transmission of ligand bias
How is bias encoded by a ligand transmitted through the receptor to downstream transducers? Our current understanding is that this is primarily accomplished through ligand-induced generation of distinct conformations of the receptor allosteric microprocessor via multiple mechanisms. First, there are changes in the receptor's secondary and tertiary structures. Then, these conformational changes result in the recruitment of proteins that post-translationally modify the intracellular loops and C-terminus of the receptor. Together, these changes in conformation and post-translational modifications contribute to differential transducer coupling. Phosphorylation and ubiquitylation of GPCRs, which alter the conformational architecture of the receptor, are the most well-described post-translational modifications that can bias signalling 71 . GPCRs require phosphorylation of serine and threonine residues within the C-terminus and intracellular loops for tight binding with β-arrestin. Multiple studies have now demonstrated that differential receptor phosphorylation patterns, or receptor 'barcodes' , lead to distinct receptor conformations or transitions that differentially couple to signalling transducers. For example, stimulation of the β 2 -AR with different biased ligands results in discrete phosphorylation patterns of intracellular residues as assessed by both quantitative phosphoproteomics and antibodies directed against phospho-specific residues 74 . With this receptor barcode, biased ligands that activate β-arrestin signalling induce conformations and trafficking patterns of β-arrestin that are distinct from those induced by unbiased ligands 74, [78] [79] [80] [81] [82] . Disrupting this barcode, through mutations in the C-terminus of GPCRs that remove putative GPCR C-terminal phosphorylation sites, can have serious physiological consequences. For example, truncation or mutation of serine or threonine residues in the C-terminus of CXCR4 causes warts, hypogammaglobulinaemia, immunodeficiency and myelokathexis (WHIM) syndrome by disrupting CXCR4 internalization and sequestering neutrophils within the bone marrow 83, 84 . Mutations that potentiate β-arrestin-receptor interactions also cause disease. A constitutively active mutation in the conserved E/DRY 'ionic lock' motif of the vasopressin 2 receptor (V 2 R) leads to constitutive receptor phosphorylation, continual β-arrestin recruitment and receptor internalization that results in nephrogenic diabetes insipidus through diminished surface expression of V 2 R and reduced aquaporin channels in renal collecting ducts 85 (FIG. 2) . Mutating highly conserved polar residues near the transmembrane helical boundaries and core of the glucagon-like peptide 1 receptor results in differential regulation of cAMP, calcium and phospho-ERK signalling and can be a trigger for biased agonism [86] [87] [88] . However, it is still largely unclear how these motifs contribute at the structural level to the transmission of biased information encoded in a ligand to the receptor and then to a transducer.
Structural basis for biased agonism
Since the first crystal structure of a non-rhodopsin GPCR, the β 2 -AR, was solved in 2007 (REF. 89 ), over 30 highresolution crystal structures of GPCRs have been determined. This structural revolution has provided invaluable insights into GPCR signalling mechanisms. These structures display a common seven-TM domain architecture, but with substantial heterogeneity in the orthosteric ligand binding pockets 90 . Receptors that bind the same ligand have increased conservation within the binding pocket. Nevertheless, most of these receptors with a common ligand generally share only 50-60% of their amino acid residues 91 . The production of homogeneous complexes necessary for crystallization often requires modification of the flexible C-terminus and other intracellular loops; therefore, many GPCR structures lack detailed information of these regions. While active GPCR structures are crucial for structure-based drug design of agonists, inactive GPCR structures provide high-resolution insight into the development of therapeutic antagonists and inverse agonists. This is true, for example, for structures of the angiotensin II (AngII) type 1 receptor (AT 1 R) in complex with AT 1 R blockers 92, 93 , a common therapeutic target for anti-hypertensive medications. Inactive structures also provide important insights into signalling mediated by the active state, as a comparison point for conformational differences between ligand-bound and unbound receptor states. There are many receptors for which both 'inactive' as well as either active or partially active intermediate crystal structures are available, including rhodopsin 94, 95 , the adenosine A 2A receptor (A 2A R) [96] [97] [98] , the M 2 muscarinic receptor (M 2 R) 99 and the μ-opioid receptor (μ-OR) 100, 101 . Structures of receptors in complex with biologically potent allosteric antagonists or negative allosteric modulators include CC-chemokine receptor 2 (CCR2) 102 , CCR9 (REF. 103 ), corticotropin-releasing factor receptor 1 (CRF 1 R) 104 and the glucagon receptor 105 . These offer high-resolution insights into druggable surfaces outside of the orthosteric ligand pocket, most notably rearrangements of amino acid contacts between TM3, TM6 and TM7 that expose residues that could lead to GEF activity and subsequent G protein activation. However, the changes observed in these structures can be quite limited.
These structures have shown that agonists alone are often not sufficient to stabilize an active GPCR conformation. Transducer coupling, or use of a stabilizing modulator such as a nanobody, is often required for trapping the receptor in its active state. To date, only three GPCR structures have been solved in complex with a bona fide G protein [106] [107] [108] . The β 2 -AR was the first such receptor-G protein complex, and the co-crystal structure reveals that both the N-terminal and C-terminal domains of the ) with respect to G protein and β-arrestin signalling. However, current μ-OR -selective agonists, such as morphine, that provide pain relief also cause adverse effects, including respiratory depression, constipation, tolerance and dependence. Both animal and human studies suggest that G protein signalling primarily mediates the analgesic efficacy, while β-arrestin signalling mediates many of the adverse effects. Strongly G protein-biased agonists, such as TRV130 and PZM21, may therefore provide clinical superiority to currently available agonists. b | Relative to the wild-type receptor, the naturally occurring human vasopressin 2 receptor (V 2 R) mutation R137H results in β-arrestin-biased signalling and is associated with familial nephrogenic diabetes insipidus. The V 2 R R137H variant is constitutively phosphorylated. This constitutive phosphorylation promotes higher β-arrestin recruitment and internalization, even in the absence of arginine vasopressin (AVP; also known as antidiuretic hormone), compared with the wild-type receptor. Presumably, a significant reduction in vasopressin-mediated Gαs signalling is sufficient to diminish aquaporin channel insertion into the renal collecting ducts, impeding urine concentration through reduced water resorption and leading to the clinical diagnosis of nephrogenic diabetes insipidus. GRK, G protein-coupled receptor kinase.
Gαs subunit interact with the β 2 -AR intracellular loop 2, TM5 and TM6. Recently, the structure of the calcitonin receptor (CTR) in complex with a Gαsβγ hetero trimeric complex was solved by cryo-electron microscopy (cryo-EM) 107 . Like the β 2 -AR, substantial outward movement of TM6 is observed. Although the β 2 -AR belongs to the class A GPCR subfamily and the CTR belongs to the class B subfamily (whose members exhibit a larger extracellular N-terminal domain compared with class A GPCRs), an overlay of the β 2 -AR-G protein and the CTR-G protein complex structures reveal only minor differences in G protein conformation between the two receptors. However, in contrast to the β 2-AR, helix VIII of the CTR appears to play a more important role in receptor stability at the cell surface and in interactions with Gβ. Indeed, growing evidence suggests an important role of helix VIII in signalling. At the enigmatic AT 2 R, helix VIII lies parallel to the membrane in the activelike state, apparently sterically inhibiting G protein and β-arrestin interactions with the AT 2 R, which is in agreement with an unusual lack of observed G protein or β-arrestin signalling for this receptor 109 .
Other GPCRs have been crystalized with G protein 'mimics' , such as nanobodies or an engineered mini-G protein model, that hold the receptor in a conformation thought to mirror the G protein activated state. These structures include the M 2 R 99 , μOR 101 , viral US28 receptor 110 and A 2A R 111 . Three distinct conformations of the β 2 -AR stabilized by different nanobodies have also been recently reported 112 . Structural information on how β-arrestins can interact with GPCRs is also beginning to emerge. Truncation of the arrestin 1 (visual arrestin) C-terminus mimics an activated arrestin, and releases a critical central-crest 'finger loop' by disrupting the polar core 113 . The structure of this finger loop bound to rhodopsin, as well as of the structure of rhodopsin bound to arrestin 1, were recently solved, providing a high-resolution view of an additional GPCRtransducer complex 114, 115 . Additional structures of GPCRs in complex with β-arrestins, as well as GRKs, will be necessary to determine whether conserved receptor-arrestin interaction patterns are also present. Such studies will reveal whether G proteins, GRKs and arrestins have preferences of specific receptor conformations. Comparisons of structures of the ligand-receptor-transducer ternary activated complex with those of the inactive receptor state are the cartographical methods of rational GPCR drug design and represent a powerful tool that is beginning to be harnessed for increasing the efficiency of drug discovery.
A range of other biophysical studies are now being used to provide high-resolution information to enable drug discovery for more challenging targets 116 . EM techniques, notably cryo-EM and negative-stain EM, have emerged as important methods for determining GPCR-transducer structures. An advantage of EM technology is the ability to study a receptor in its wildtype form, as X-ray crystallography frequently requires receptor modifications to obtain sufficient homogeneity and stability for crystal formation. In addition to high-resolution structures such as the CTR-G protein complex described above, low-resolution structures from negative-stain EM have been used to reveal agonist-occupied β 2 -AR in complex with G proteins as well as to capture transient intermediate G protein and β 2 -AR complexes 117 . Furthermore, EM of a β 2 -AR and V 2 R chimeric receptor (utilized to increase β-arrestin affinity) demonstrates that β-arrestin can adopt at least two distinct conformational states when interacting with a GPCR. One conformation reveals β-arrestin bound only to the phosphorylated C-terminus of the receptor, while a separate conformation demonstrates the flexible 'finger loop' of β-arrestin inserting into the receptor transmembrane core in addition to the C-terminus interaction 118 . The functional significance of these distinct β-arrestin-receptor interactions (C-terminus only and C-terminus plus core) has also been studied. Partial engagement of β-arrestin with the C-terminus appears to be sufficient for receptor endocytosis and ERK activation 119 . Contact of the β-arrestin finger loop with the receptor transmembrane core appears to be necessary for desensitization, with negative-stain EM providing support that a finger loop-core interaction sterically blocks the apparent G protein binding site 120 . Negativestain EM studies have also revealed that internalized receptor complexes can consist of a GPCR, β-arrestin and G protein 121 . Such internalized 'megaplexes' demonstrate that a single GPCR can simultaneously interact with both a β-arrestin and a G protein. Visualization of these 'megaplexes' provides a molecular basis for sustained GPCR catalytic GEF activity and subsequent G protein signalling following GPCR internalization into endosomes. Taken together, the existing EM studies lend further structural support for the presence of multiple GPCR 'active' conformational states.
Additional experimental approaches, including a high-resolution mass spectrometry labelling strategy, NMR, molecular dynamic simulations, conformationally selective RNA aptamers and single-domain camelid antibodies (nanobodies) 112, [122] [123] [124] , have shown that functionally similar ligands can induce distinct receptor conformational changes. For example, 19 F NMR spectroscopic analysis of the β 2 -AR demonstrated distinct receptor conformational states when bound to balanced or biased ligands. The US Food & Drug Administration (FDA)-approved β-blocker carvedilol, which has been proved to be particularly effective for the treatment of heart failure, is a moderately β-arrestin-biased agonist of the β 1 -AR 125, 126 and β 2 -AR 127 . A comparison of β 2 -AR conformations induced by either the balanced agonist isoprenaline or the β-arrestin-biased agonist carvedilol revealed that G protein activity correlates with movement of transmembrane helix VI, whereas carvedilol chiefly alters the conformation of helix VII (REF. 128 ). RNA aptamer binding also revealed specific β 2 -AR conformations induced by different ligands 129 , and 13 C-labelled β 2 -ARs further validate distinct receptor states not captured by previous crystal structures 130 . Double electron-electron resonance (DEER) spectroscopy of a trifluoro-methyl-labelled cysteine at TM6 of the β 2 -AR has also shown substantial conformational heterogeneity and rapid interconversion of multiple receptor states 131 .
In addition to β 2 -AR, a multitude of active receptor conformations are observed at the ghrelin receptor 132 and the 5-hydroxytryptamine 2B (5-HT 2B ) receptor (also known as the serotonin 2B receptor) 133 , demonstrating that a hetero geneous ensemble of active receptor states is a conserved property. β-Arrestin biosensors have also recently been employed to correlate the conformational signature of arrestins to predict signalling and trafficking functions following drug stimulation 81, 82 . β-Arrestin NMR probes show that different β-arrestin-phosphopeptide interactions encode distinct structures that correlate with specific β-arrestin-mediated functions 134 . In summary, most structural studies support a model of the receptor as an allosteric microprocessor, with biased ligands inducing an array of distinct receptor conformations that differentially recruit and activate transducers. , a ligand is considered to have two primary properties in its interactions with a receptor: affinity (the ability of a ligand to form a ligand-receptor complex) and efficacy (the ability of the ligand-receptor complex to increase or decrease downstream signalling responses). In mechanistic models of receptor signalling, such as the ternary complex model, efficacy is a measure of the ability of a ligand to effect the transition between active and inactive receptor conformations (such as the α-parameter in the ternary complex model), while in pharmacological models, efficacy relates the pharmacological stimulus to the observed response 136 . These pharmacological and mechanistic estimates of efficacy are mathematically closely related 40 . As noted above, the concept of biased agonism requires that a receptor display multiple efficacies, and determination of these biased efficacies requires a deconvolution of ligand bias from system bias. Multiple approaches have now been proposed to quantify ligand bias [139] [140] [141] , although identifying biased ligands requires multiple steps, from the choice of assays used to assess different signalling pathways to the computational approaches used to quantify ligand bias. TABLE 1 provides a summary of different experimental techniques that can be utilized to measure signal transduction effects. Broadly speaking, these assays are based on different aspects of transducer activity, which include transducer redistribution, receptor-transducer proximity, transducer conformation, receptor internalization and transducer signalling. Redistribution assays are based on the movement of a transducer either to or away from the receptor or downstream effector with ligand stimulation. Receptor proximity assays quantify changes in the distance of a population of transducers, such as β-arrestins, to a GPCR upon agonist binding. Assays of transducer conformation and signalling require a clear understanding of the relationship between the measured effect and transducer activity. For example, while β-arrestin activation is associated with conformational changes, only certain conformational signatures are associated with specific signalling function, such as receptor internalization 81 . Indeed, receptor internalization does not always require β-arrestin recruitment, or vice versa 142 . Some signalling assays may have inputs from multiple upstream transducers, such as MAPK phosphorylation, which has distinct inputs from both G proteins and β-arrestins.
Quantifying bias

Detecting transducer signalling
When designing experiments to identify biased agonists, it is important to eliminate sources of system bias that can confound data interpretation. Comparisons of efficacies and potencies from assays are often limited by differences in receptor reserve (also known as 'spare receptors') or amplification between assays. In assays with substantial amplification, such as G protein second-messenger assays, both full and partial agonists can reach the same maximal response. In assays with negligible signal amplification, such as bioluminescence resonance energy transfer (BRET)-based recruitment or dissociation assays, a balanced partial agonist will display less efficacy relative to a full agonist. With a simple comparison of potencies or maximal responses, a partial balanced agonist that yields a half-maximal response in assay B and a maximal response in the amplified assay A could incorrectly be labelled as a biased ligand relative to the full balanced agonist that achieved maximal responses in both assays. Potencies are also affected by amplification. In assays with high amplification, a full agonist will have a greater leftward shift in potency (effective concentration for half-maximal response (EC 50 )) from its dissociation constant (K d ) than a partial agonist. However, in assays with no or minimal receptor reserve, the EC 50 will approximate the K d for a partial agonist, but not for a full agonist. It can be difficult to compare proximal and distal signalling effectors due to varied amplification and system bias 143 . Thus, it is not straightforward to compare the maximal effect (E max ) and EC 50 alone to identify biased agonists. To address this issue, both qualitative and quantitative approaches have been developed to attempt to remove the effects of system bias and identify truly biased ligands.
Identifying biased ligands
To increase the sensitivity and specificity of identifying biased compounds, both quantitative and qualitative methods should be used to identify potentially biased ligands. The effects of system bias can be assessed qualitatively by using a 'bias plot' (REF. 144) (FIG. 3) . Bias plots are generated by converting dose-response data for two signalling pathways of interest, for example, G protein and β-arrestin, into plots comparing responses in pathway A to responses in pathway B at identical concentrations of ligand 143, 144 . An advantage of the bias plot is that it allows an assessment of assay amplification effects that can confound efforts to identify biased ligands. It also provides a way to identify the best assays to quantify ligand bias, as it provides information on the windows for identifying G protein-biased or β-arrestinbiased agonists. When choosing assays to assess ligand bias, it is important to select assays that have similar levels of amplification. Similar levels of amplification provide larger windows for identifying ligands that could be biased towards either pathway tested. However, if one is interested in identifying ligands biased towards pathway A relative to pathway B, it can make sense to choose an assay with somewhat more amplification in pathway B relative to pathway A. If a ligand does not appear to be biased using a bias plot, it is unlikely to be biased, even if a 'bias factor' from a quantitative approach is significant. This is because the bias plot is not prone to errors introduced from different fitting approaches 40 . However, even bias plots cannot account for other aspects of system bias, such as differential expression of GRKs and β-arrestins, which can qualitatively change the relative difference between downstream pathways.
Common questions regarding ligand bias
What assays should I use to identify biased agonists? In general, it is best to choose assays with similar levels of amplification. However, if one is interested in specifically identifying G protein-biased or β-arrestin-biased agonists, assays can be chosen to maximize the 'window' for identifying such ligands
. For example, if screening is performed for a G protein-biased agonist, the window for identifying such agonists could be maximized by using an assay for G proteins that has less amplification than that for β-arrestins (FIG. 3) . While increased amplification allows the identification of weak partial agonists, it can result in artificial stoichiometric relationships between interacting proteins and a risk of artefacts. If strong partial or full agonists are studied, assays with low or endogenous receptor expression may be better. Ideally, the assays used should be carried out in a cell type that is physiologically relevant, thereby limiting the effects of system bias on the in vitro and in vivo drug profiles.
What is the best way to calculate ligand bias? All the approaches discussed (BOX 1) have strengths and weaknesses. A bias plot should always be used to assess for bias qualitatively -if bias is not visualized on a bias plot, it is unlikely to be present. All the quantitative approaches • Minimize differences in pathway amplification • Optimize the window for identifying biased agonists
• Rule out significant kinetic effects • Rule out significant cell-specific effects
• Confirm that biased signalling is maintained in the model receptor using the same assays • If bias is not conserved, then consider using a different model or a humanized model system • Utilize genetic manipulations to confirm target and pathway specificity while appreciating the limitations of such approaches
Steps to identify bias Approach
Figure 3 | General approach to characterizing biased ligands. First, assays for different pathways should be chosen with the goal of minimizing differences in signal amplification. Such assay selection optimizes the window for identifying biased agonists (see example of a bias plot). Time-dependent and cell-dependent data should be obtained to ensure that there are no significant kinetic or cell-specific effects. To qualitatively identify biased agonists, construct a 'bias plot' by, for example, graphing β-arrestin activity on the x axis and G protein activity on the y axis (each normalized to pathway-specific maximal signals in this example). Deviations from the reference agonist suggest the presence of ligand bias. If no biased signalling is observed on a bias plot, then it is unlikely that true biased signalling is present (even if calculated bias factors are statistically significant). Multiple approaches can be used to calculate bias factors
, such as a method based on intrinsic relative activities (calculator available online). After identification and quantification of ligand bias, the physiological implications of such signalling can be tested in relevant cell lines or primary cells. Biased signalling properties can then be confirmed in the receptor from a relevant model organism and subsequently evaluated in animal models for safety and efficacy.
to assess bias are based on essentially the same framework of the operational model, although with different assumptions. If the data are fit well without Hill coefficients and no binding data are available, using the approach of intrinsic relative activities is straightforward and can provide estimates for bias. If the Hill coefficient is non-unity and no binding data are available, transduction coefficients should be used. If binding data are available, the approach of effective signalling can also be used.
My ligand signals through G proteins and β-arrestinshow could it be biased?
Biased and balanced signalling are relative terms. First, it is nearly impossible to state that a receptor signals 'equally' to different transducers, unless an assay is performed to assess changes in binding of transducers at the receptor 145 , which would place signalling through different transducers on the same scale. Rather, nearly all measurements are made through the lens of observation bias and reflect amplification at different levels. For that reason, accepted approaches to Nature Reviews | Drug Discovery . For example, for the signalling of ligand 1 compared with a reference compound in pathway A, the RA i is as follows:
A clear indication of biased signalling between two ligands is whether the rank order of RA i changes from one pathway to another within the same system. These ratios are also mathematically identical to transduction coefficients (τ/K a ) when the Hill slope is unity 141 ; thus, this method is mathematically identical to the 'transduction coefficient' method for most concentration-response data (see below). Bias can also be quantified through the calculation of a bias factor, β, when comparing signalling through two pathways 139 
:
This bias factor quantifies the degree of ligand bias on a logarithmic scale; for example, a bias factor of 1 corresponds to tenfold higher signalling through pathway A compared with pathway B. The strength of this approach is that it can provide estimates of bias relatively free of any underlying receptor model from simple fits of concentration-response data (unlike bias factors from the operational model, which require either a dissociation constant or a more complex fitting routine; see below). Limitations of calculating bias through RA i values include that it can only be applied to data with a Hill coefficient of 1 and that it does not provide an estimate of the underlying efficacy of the ligands tested (it only provides an estimate of bias). A calculator for intrinsic relative activity values is available online (see Further information).
Approaches for quantifying bias using the operational model
The operational model developed by Black and Leff is a pharmacological model that accounts for efficacy (quantified by the factor τ) and affinity (K a ) by considering the agonist-receptor complex as the functional unit that leads to a pharmacological effect:
where the variable n accounts for a dose-response curve with a non-unity Hill coefficient (although the curve obtained from an operational model fit is different to a typical dose-response curve with a Hill coefficient); τ accounts for efficacy and system amplification and is equal to the receptor density (R t ) divided by the receptor-transducer coupling efficiency (K E ) 215 ; K a is the ligand association constant; and E m is the maximal response of the system induced by a full agonist. While the operational model assumes that signalling is directly related to the agonist-receptor complex and accounts for receptor concentration and intracellular amplification, mathematically it is nearly identical to other pharmacological receptor models 40 .
Transduction coefficients: assessing bias through functional affinity
In the approach using 'transduction coefficients', which are defined as τ/K a , a 'functional affinity', K a , as opposed to one obtained from a separate binding study, is used to fit the data. As noted earlier, for dose-response data with a Hill coefficient of 1, the transduction coefficient should be mathematically identical to the RA i . Therefore, a similar approach can be used to yield a bias factor. Namely, a reference transduction coefficient is utilized to compare values for a given agonist between the pathways of interest, providing a Δlog(τ/K a ). A measure of relative bias (ΔΔlog(τ/K a )) is then calculated by comparing a ligand of interest to a reference ligand 140 
:
A strength of this approach is that it does not require separate experiments to obtain dissociation constants for ligands. For partial agonists, this can result in an excellent fit of the data, as there is a clear relationship between potency and K a . Unlike the RA i values, this approach can also be used to fit data with a Hill coefficient of non-unity. There are also some limitations of this approach. First, there can be ambiguity in the K a for full agonists where there is not a clear relationship between potency and functional affinity. Second, this analysis only provides information on bias and not on the underlying efficacies for signalling through different pathways. These advantages and limitations of this model have been noted elsewhere [216] [217] [218] .
Effective signalling: estimates using the operational model If dissociation constants from an independent binding study are available, such data can be used in the operational model to yield not only estimates of bias, β lig , but also of the effective signalling for each ligand, σ lig = τ lig -τ ref (REF. 139) . A strength of this approach is that it provides estimates for both bias and efficacy for each ligand. This is an advantage, as a strongly biased weak partial agonist will have significantly different effects than a strongly biased full agonist. This approach can also be used to fit data with a non-unity Hill coefficient. However, there is a major limitation to this approach because of the requirement for having dissociation constants for each ligand. These dissociation constants must be obtained in conditions similar to the signalling assay with decoupling from potential transducers (as shifts in binding associated with transducer coupling are directly related to efficacy 145 ). Even with those conditions, partial agonists may display significant differences between EC 50 and K d that cannot be accounted for in a pharmacological model. In such a situation, either RA i values or transduction coefficients should be used.
quantifying bias are carried out in comparison to a reference agonist, which, by convention, is usually referred to as 'balanced' . It is possible that the endogenous reference agonist may have a significant difference in E max in two assays, while a synthetic ligand reaches a higher E max in both assays. This would not make the synthetic ligand 'balanced'; rather, it is biased relative to the reference agonist.
How should I calculate maximal response and potency?
A typical first step in concentration-response analysis is to fit the measured efficacy to varied concentrations of a drug, typically with a standard three-parameter curve fit utilizing the minimum, maximum and EC 50 . Introduction of additional variables, such as the Hill coefficient, may improve the fit but should only be used if it provides a substantial improvement. Poor curve fits that result in a suboptimal definition of the minima, maxima and/or EC 50 will introduce substantial error into a bias calculation. Baseline correction of the minima to zero is sometimes necessary in high-throughput assays, especially if the lowest concentration of ligand is on the outer wells of 96-well or 384-well plates, which are at increased risk of suffering from small concentration deviations due to increased evaporation of solvent relative to the inner wells.
Can I still calculate bias with a poor fit? Curve fits that have poorly defined minima, or more commonly maxima, introduce substantial error into bias calculations. If the maximal response is poorly defined, and increasing the concentration of the ligand is not feasible, then how can a model system be altered to produce an improved fit? One method is to increase expression of the receptor or transducers, such as G proteins, GRKs and/or β-arrestins; however, one must be very cautious of this approach. Artificial stoichiometric relationships between interacting proteins, such as the receptor:transducer ratio, can produce misleading results. In circumstances where receptors are promiscuous with respect to the G protein isoforms they interact with, high receptor numbers may recruit G protein isoforms that have an opposing signal or activate alternative pathways that would not be found in the tissue of interest. In addition, high levels of β-arrestin overexpression may dramatically alter the kinetics of the assay through potentiated desensitization and/or increased receptor internalization.
Translational utility of in vitro bias
Many of the strategies used to bring a promising biased ligand from the bench to bedside are similar to those for typical drug candidates and have been reviewed elsewhere [146] [147] [148] [149] . Given the considerable costs in late-phase drug discovery, accurately quantifying the relative signalling properties of biased agonists early in the drug discovery process, as well as evaluating effects in suitable preclinical models of disease, is necessary. A number of approaches for biased ligand drug discovery can build confidence that the observed physiological effects are due to bias at the intended target and pathway (FIG. 3) .
Often, the first step in testing a biased drug is in heterologous expression systems. At this stage, it is important to use pharmacological assays that allow an accurate assessment of bias, which in practice most often means selecting signalling assays with similar levels of amplification. If biased signalling is noted in a heterologous expression system, the candidate can then be tested in primary cells or a cell line that best models the tissue being targeted to minimize any potential system bias due to different levels of transducer expression from the heterologous expression system. Testing the ligand in human cells and/or tissue before direct human trials provides further validation. Before studying the compounds in model organisms to test safety and efficacy, it is crucial to confirm that the drug binds and that bias is conserved at the receptor of a model organism. For example, a mouse receptor should be evaluated in hetero logous expression systems in the same assays used to test a human receptor. After confirming binding and biased signalling at the receptor of a model organism, the ligand can be advanced with more confidence. Frequently it is helpful to perform experiments with a biased candidate in parallel with balanced agonists and antagonists, to confirm that the effects of the candidate are due to bias and not to simple agonism or antagonism. The use of genetically altered animal models can provide further data about the mechanism of action. For assessing biased ligands, knocking out the receptor target can confirm that it mediates the biological effect, and removing or altering a presumed critical transducer (such as a G protein or β-arrestin isoform) that the candidate is biased towards can provide strong evidence regarding the specific pathway or pathways involved. Caution is warranted when interpreting a phenotype from models lacking a critical transducer, even from conditional knockouts, as these transducers almost always couple to multiple receptors and signalling pathways. Some transducers have overlapping roles, such as the two isoforms of β-arrestins, and knocking out the dominant isoform in the tissue of interest is often necessary when dual or multiple knockouts are lethal or not feasible. As in all genetic manipulations, compensation and alternative pathway selection are additional confounding factors to consider.
Biased physiology
Biased agonism has the potential to revolutionize GPCR drug discovery. For this reason, groups in academia and industry have active research programmes in this area. It is impossible to provide a full description of all the biased agonists whose effects have been tested in preclinical or clinical studies. Rather, we focus on a few examples that demonstrate the promise of these agents as novel therapeutics. TABLE 2 provides an abbreviated and incomplete list of therapeutically promising biased ligands under active investigation.
μ-Opioid receptor
The μ-OR, with its endogenous agonists of enkephalin peptides, is the target of multiple blockbuster drugs. Exogenous opioid agonists of the μ-OR, such as morphine and fentanyl, provide analgesia, while antagonists, such as naloxone and its derivatives, are used in the treatment of opioid overdose and substance abuse. However, current μ-OR agonists are limited by side effects that include addictive potential, respiratory depression, constipation and tolerance. Compared with the endogenous agonists of μ-OR, the enkephalins, morphine induces considerably less receptor phosphorylation and internalization (consistent with bias towards G protein-mediated signalling), while etorphine, fentanyl and methadone cause robust receptor internalization in cells without high levels of GRKs 150, 151 . Intrinsic efficacies of G protein signalling for several μ-OR agonists do not correlate with the rank order of agonist-induced internalization efficacy, consistent with ligand bias 152 . Early studies of β-arrestin signalling at the μ-OR suggested that a G protein-biased agonist might display increased analgesia with a reduced side-effect profile 153, 154 . Such small molecules have since been developed: herkinorin 155 (derived from the naturally occurring plant product salvinorin A), TRV130 and PZM21. The G protein-biased μ-OR agonist TRV130 increased both analgesia and pain relief while reducing on-target adverse effects compared with morphine in a randomized, double-blind controlled trial 156, 157 . PZM21, which is structurally distinct from previously explored μ-OR ligands, was discovered via the use of computational modelling and structure-based optimization strategies 158 . Like TRV130, PZM21 displayed a potent Gαi signalling profile, limited β-arrestin recruitment and selective μ-OR activity and provided improved analgesia with fewer side effects compared with morphine in a preclinical pain model (FIG. 2) .
κ-Opioid receptor
Like the μ-OR, κ-OR signalling can produce analgesia, but unlike drugs targeting the μ-OR, κ-OR agonists have a low risk of dependence and abuse. However, the distinct side-effect profile of κ-OR activation by the receptor-selective, high-efficacy agonists initially developed included psychotomimesis, dysphoria and sedation 159, 160 . Recent studies have established that the analgesic effects are Gβγ-mediated, whereas the aversive effects require β-arrestin-mediated activation of p38 MAPK, which regulates serotonin transporter and inward-rectifying potassium channel function in neurons of reward processing centres, such as the dorsal raphe nucleus and ventral tegmental area [161] [162] [163] . The G protein-biased κ-OR ligand triazole 1.1 retained the antinociceptive and antipruritic efficacies of a conventional κ-OR agonist but did not induce sedation, reduce dopamine signalling or produce dysphoric-like behaviours in rodent models 164 . Additional biased κ-OR agonists are currently being developed and may provide the precision necessary to successfully drug a very promising clinical target 70, [165] [166] [167] [168] [169] [170] . The κ-OR system also shows interesting ligand bias in antagonist drug action: some are conventional competitive ligands with low efficacy, and some are orthosteric ligands that initiate a different mode of signalling that results in long-lasting receptor inactivation [171] [172] [173] . The implications of this ligand bias are clinically significant because κ-OR antagonists show therapeutic promise in the treatment of stress disorders underlying depression and addiction risks 174, 175 .
Dopamine D2 receptor
The Gαi-coupled D 2 R is the most common target of antipsychotic drugs. The dopamine hypothesis of schizophrenia proposes that the molecular aetiology of this disease is manifested in part by cortical hypodopaminergia and subcortical hyperdopaminergia 176 . β-Arrestins and GRKs are differentially expressed in the cortex and subcortical regions, with GRK2 and GRK3, and to a lesser extent GRK6, being reduced in the striatum compared with the prefrontal cortex in both rodents and humans 69 . Due to system bias in these tissues, it is theoretically possible for a balanced ligand to exhibit differential β-arrestin and G protein signalling between the striatum and cortex. Interestingly, using genetically engineered mice lacking β-arrestin 2 in a select population of neurons, Urs, Caron and colleagues 69 have demonstrated both electrophysiologically and behaviourally that while D 2 R signalling is inhibitory in the striatum, it is excitatory in the cortex but depends on both GRK2 and β-arrestin 2. A β-arrestin-biased agonist could therefore theoretically further exploit the observed system bias by reducing dopaminergic signalling in the striatum while mitigating cortical hypodopaminergia and increasing excitatory signalling. Biased D 2 R ligands have been identified 177, 178 , including β-arrestin-biased agonists identified through structure-function studies based on derivations of the FDA-approved antipsychotic aripiprazole 179, 180 . In animal models, the D 2 R-selective, β-arrestin-biased ligands UNC9975 and UNC9994 improve animal behaviours that are used to model schizophrenia phenotypes, reducing dopamine-dependent hyperlocomotion, restoring pre-pulse inhibition and normalizing social behaviour 69, 181 . However, whether these ligands will correct cortically associated memory and executive dysfunction remains to be established 182 . Interestingly, these β-arrestin-biased D 2 R ligands appear to have an improved side-effect profile compared with typical antipsychotics, with significantly lower levels of catalepsy compared with haloperidol 181 .
Calcitonin receptor
Similar to other Gαs-coupled GPCRs, calcitonin binding to the CTR increases cAMP production, β-arrestin recruitment, calcium mobilization and ERK activation. Calcitonin signalling through the CTR reduces serum calcium, primarily by inhibiting osteoclast activity and reducing renal tubular cell reabsorption of calcium phosphate 183 . Salmon calcitonin (sCT), which is approved by the FDA for the treatment of postmenopausal osteoporosis, provides a modest increase in bone density by reducing the rate at which osteoclasts degrade bone tissue. However, its peptide formulation and modest clinical efficacy limit the current clinical benefits of sCT. Recent studies demonstrate that sCT has a decreased rate of dissociation from the human CTR and increased β-arrestin recruitment compared with human calcitonin (hCT) 184 . Beyond differences in β-arrestin signalling, additional granularity of ligand bias is apparent at the CTR, as hCT and sCT appear to induce unique receptor-transducer conformations. Interestingly, the hCT-occupied ternary complex was disrupted by GTP at an approximately tenfold lower GTP concentration than for sCT-occupied ternary complexes. Together, these findings demonstrate that ligand-dependent G protein ternary complexes mediate GTP affinity by distinct changes in G protein conformation 185 . This suggests that, similar to the different signalling effects promoted by distinct β-arrestin conformations, G proteins can adopt discrete active states with distinguishable signalling characteristics.
Chemokine receptors
Until recently, it was unclear whether biased agonism was a by-product of GPCR complexity that can only be exploited by synthetic drugs or whether it is a property that has evolved within GPCR systems as an additional layer of signalling specificity. We now appreciate that some endogenous ligands are biased agonists. One group of GPCRs for which endogenous bias is crucial is the chemokine system, consisting of over 50 ligands and 20 chemokine receptors that bind one another with substantial redundancy and promiscuity 186, 187 . For example, the chemokine receptor CXCR3A, which plays important roles in inflammation, vascular disease and cancer, has four known endogenous ligands: CXC-chemokine ligand 4 (CXCL4; also known as PF4), CXCL9, CXCL10 and CXCL11 . CXCL10 and CXCL11 signal through Gαi to inhibit cAMP generation with equivalent potency and efficacy that exceeds that of CXCL4 and CXCL9 (REF. 59 ). By contrast, CXCL11 is more potent and efficacious in recruiting β-arrestin to CXCR3A than are the other three endogenous ligands, and the rank order of efficacy for CXCR3A internalization is the same as for β-arrestin recruitment 191 . In addition, CXCL11 promotes CD4 + T cell polarization into forkhead box protein P3 (FOXP3)-negative regulatory T cells via signal transducer and activator of transcription 3 (STAT3)-dependent and STAT6-dependent pathways, while CXCL9 and CXCL10 promote CD4 + T cell polarization into effector T helper 1 (T H 1) and T H 17 cells via STAT1-dependent, STAT4-dependent and STAT5-dependent pathways 192 . β-Arrestin-biased and GRK-biased chemokines have also been described at other chemokine receptors, including CXCR2, CCR1, CCR5 and CCR7 (REFS 67, 191, 193) . Similar to many chemokines, the endogenous CXCR4 ligand CXCL12 (also known as stromal cell-derived factor 1 (SDF1)) can exist in monomeric or dimeric forms. Monomeric CXCL12 signals via both G protein and β-arrestin pathways through CXCR4, while dimeric CXCL12 signals through G proteins with minimal-to-absent β-arrestin recruitment and signalling 194 . Demonstrating further granularity of biased signalling, different chemokines can exhibit G protein subunit bias, as endogenous chemokines for CCR5 and CCR7 signal through overlapping but distinct G protein subtypes 195 . In addition to endogenous biased signalling, biased synthetic small molecules with affinity for chemokine receptors have also been identified 196 . Biasing chemokine receptor signalling may provide an avenue for drugging a GPCR family that has been notoriously difficult to therapeutically target.
Angiotensin receptor AT 1 R signalling regulates multiple functions controlling blood pressure and serum osmolality, including vasoconstriction and aldosterone secretion. AT 1 R antagonists, including the sartan class of small molecules, are used in the treatment of hypertension, heart failure and diabetic nephropathy. AngII binding to the AT 1 R activates both Gαq and Gαi as well as β-arrestin transducers. The first example of a β-arrestin-biased ligand was SII angiotensin, a synthetically modified form of AngII that binds to the AT 1 R 30 . AT 1 R agonists more strongly biased towards β-arrestin, such as the peptide TRV027, have recently been explored as drugs to treat decompensated heart failure. At AT 1 R, Gαq protein signalling mediates vasoconstriction and cardiac hypertrophy, whereas β-arrestin signalling results in modest positive inotropy, desensitization of G protein signalling, receptor internalization, activation of anti-apoptotic signals and volume-dependent enhancement of cardiac contractility 197, 198 . In addition, AT 1 R-mediated β-arrestin 1 signalling promotes an increase in intracellular calcium concentration in primary chromaffin cells distinct from Gαq-phospholipase Cβ (PLCβ)-mediated calcium flux by directly coupling to ion channels such as the transient receptor potential cation channel subfamily C3 (TRPC3) 199 . In animal models of heart failure, TRV027 and other AT 1 R β-arrestin-biased ligands are cardioprotective and thought to act by reducing afterload while increasing cardiac performance and maintaining stroke volume. Like other first-in-class drugs, the development of biased compounds has been met with hurdles: TRV027 recently failed to meet established end points for decompensated heart failure in a phase IIb clinical trial 197 .
Adenosine receptors
Adenosine is a purine nucleoside with cardioprotective properties 200 . Four isotypes of the adenosine receptor have been identified, all of which are expressed in cardiac tissue, among other regions. The A 1 R couples primarily to Gαi/o, the A 2A R to Gαs, the A 2B R to both Gαs and Gαq, and the A 3 R to Gαi/o 201, 202 . It is currently unclear which receptor or receptors mediate the cardio protective effects of adenosine. On-target adenosine-mediated side effects, including bradycardia, atrioventricular conduction blockade and hypotension, limit the clinical utility of adenosine following cardiac ischaemia. Therefore, a ligand that recapitulates the cardioprotective effects of adenosine without heart rate reduction would be superior to adenosine. A screen for biased adenosine orthosteric ligands at adenosine receptors was unsuccessful; however, a 2-amino-3-benzoylthiophene allosteric modulator was identified that promotes biased G protein and ERK signalling in the presence of an orthosteric agonist 203 . Using this allosteric modulator as a backbone, the rational design of a bitopic ligand for the adenosine receptor was undertaken, producing the compound VCP746 with a mixed pharmacological profile consisting of both competitive (at low concentrations of antagonist) and non-competitive (at high concentrations of antagonist) activity. This signalling profile would be predicted for a bitopic ligand binding with high affinity to the orthosteric site and lower affinity to an allosteric site 204 . In proof-of-concept studies, VCP746 provided a cytoprotective benefit to rat cardiomyocytes and stimulated anti-fibrotic signalling pathways in both cardiac-derived and renal-derived cell lines without concomitant reduction in rat heart rate 202, 205 . Additional biased ligands at the A 3 R have been identified that promote differential activation of phosphorylated AKT, phosphorylated ERK and Gαi, as well as calcium influx and cell survival 206 .
Other promising leads Exploration of additional GPCR biased allosteric modulators has identified promising preclinical leads, including ML314, a neurotensin receptor, β-arrestin-biased allosteric small molecule agonist for the treatment of methamphetamine abuse 207, 208 . Peptide-based biased ligands are also being developed, including the short lipidated peptide (known as a pepducin) ATI-2341, which targets CXCR4 and acts as a Gαi-biased allosteric ligand that mobilizes bone marrow polymorphonuclear neutrophils 209 . The 5-HT 2B receptor was recently crystalized with the psychoactive small molecule lysergic acid diethylamide (LSD) 210 , providing structural insight into the β-arrestin-biased signalling properties of LSD and the chemically related ergolines at the 5-HT 2B receptor 133 . In addition, biased ligands have been identified at both the cannabinoid receptor 1 (CB 1 R) and CB 2 R 211 , including the β-arrestin-biased and ERK-biased allosteric modulator ORG27569, which stabilizes distinct conformations of the CB 1 R compared with traditional agonists and antagonists. This compound may provide antinociceptive and/or appetite-stimulatory signals that are distinct from effects on psychosis or cognitive function 212, 213 . Furthermore, β-arrestin-biased agonists of the free fatty acid receptor 1 (FFAR1; also known as GPR40) may prove useful in stimulating insulin secretion 214 . Further screens for biased ligands are likely to identify a trove of promising drug candidates at multiple receptors.
Conclusions
The paradigm of biased agonism, that different ligands can generate discrete receptor conformations that lead to distinct biological processes, is supported by numerous structure-function and pharmacological studies. These studies suggest that GPCRs act as allosteric microprocessors as opposed to binary 'switches' . Basic and translational studies conducted within the past 5 years have led to the explosion of promising compounds with putative biased signalling and demonstrate that the therapeutic potential for biased GPCR ligands is profound. The discovery of alternative GPCR signalling pathways, such as those mediated by β-arrestin, warrants the application of drug screening techniques beyond technologies that focus solely on proximal signalling responses mediated by G proteins. In addition, screening methods that are unable to identify allosteric ligands are likely to overlook potentially useful drugs. It is imperative to note the limitations of screening assays, especially when identifying potentially biased ligands. Bias plots, combined with quantification methods based on intrinsic relative activity, functional affinity and/or the operational model, are reasonable depending on the context and physiology of the system of interest. The available preclinical data suggest that selectively targeting G protein, β-arrestin or other non-canonical signalling pathways, depending on the physiological response desired, could improve current GPCR-based therapies through increased efficacy and reduced side-effect profiles. The true therapeutic potential will not be realized until more biased ligands are tested in preclinical and clinical trials. Given the substantial costs of late-phase drug discovery, accurately quantifying the relative signalling properties of biased agonists early in the drug discovery process and their effects in suitable preclinical models of disease is necessary. Beyond their potential therapeutic superiority, biased ligands can also be employed as tool compounds which, when combined with advances in signalling pathway analysis, can be used to dissect fundamental biological processes. Such use of biased ligands as tools will help to advance our basic understanding of intracellular signalling.
Orthosteric site
The site on a receptor to which the endogenous ligand binds.
Allosteric site
A binding site on a receptor that is different from the orthosteric site.
